BioPharm International
September 01, 2008
Columns and Departments
21
9
There are several challenges associated with protecting patents for personalized medicines.
September 01, 2008
Columns and Departments
21
9
Statistical methods for calculating confidence intervals, tolerance intervals, and capability analysis to reduce out-of-specification situations.
September 01, 2008
Features
21
9
Scalable method to recover plasmid-DNA.
September 01, 2008
Columns and Departments
21
9
Every biotech company reaches a point in its development where it must decide what path it will take after it passes the start-up phase. This article discusses what the company must consider to decide what business model it will follow.
September 01, 2008
Features
21
9
How to implement a risk-based approach to eliminating viruses.
September 01, 2008
Columns and Departments
21
9
The heparin debacle and other crises involving imported drugs and biologics has put pressure on the US FDA to step up its oversight of foreign drug manufacturing.
September 01, 2008
Columns and Departments
21
9
Risk mitigation should be a key aspect of any contract manufacturing organization's business strategy.
September 01, 2008
Columns and Departments
21
9
The complexity of Quality by Design leads naturally to questions of how much work it requires, how many companies have the resources to do it, and what the payoff is for anybody.